Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Biotie Therapies Inc.
With
Michael J. Fox Foundation for Parkinson's Research
Massachusetts General Hospital
Acorda Therapeutics
This study includes a Screening Period of up to 6 weeks, a 16 week Treatment Period, and a 2 week Safety Follow Up Period.
Final eligibility will be determined at the Baseline Visit. Eligible patients will be randomized to receive placebo or SYN120 100 mg once a day (QD).
Age
50–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Parkinson's Disease Dementia
Patient has a routine caregiver
Taking a stable cholinesterase inhibitor.
Patient has a Montreal Cognitive Assessment (MoCA) 10-23 inclusive
You may not be if
History of any significant neurologic or psychiatric disease other than PD
Any other condition or clinically significant abnormal findings that would make the patient unsuitable for the study
Unpredictable motor fluctuations that would interfere with administering assessments
Clareo Health | SYN120 Study to Evaluate Its Safety, Tolerability and Efficacy in Parkinson's Disease Dementia (SYNAPSE)
